Cargando…

Identification of Urine Metabolic Biomarkers for Vogt-Koyanagi-Harada Disease

The diagnosis of Vogt-Koyanagi-Harada (VKH) disease is mainly based on a complex clinical manifestation while it lacks objective laboratory biomarkers. To explore the potential molecular biomarkers for diagnosis and disease activity in VKH, we performed an untargeted urine metabolomics analysis by u...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Rui, Zhu, Ying, Xu, Jing, Chen, Lin, Su, Guannan, Kijlstra, Aize, Yang, Peizeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947328/
https://www.ncbi.nlm.nih.gov/pubmed/33718374
http://dx.doi.org/10.3389/fcell.2021.637489
_version_ 1783663201365262336
author Chang, Rui
Zhu, Ying
Xu, Jing
Chen, Lin
Su, Guannan
Kijlstra, Aize
Yang, Peizeng
author_facet Chang, Rui
Zhu, Ying
Xu, Jing
Chen, Lin
Su, Guannan
Kijlstra, Aize
Yang, Peizeng
author_sort Chang, Rui
collection PubMed
description The diagnosis of Vogt-Koyanagi-Harada (VKH) disease is mainly based on a complex clinical manifestation while it lacks objective laboratory biomarkers. To explore the potential molecular biomarkers for diagnosis and disease activity in VKH, we performed an untargeted urine metabolomics analysis by ultra-high-performance liquid chromatography equipped with quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF/MS). Through univariate and multivariate statistical analysis, we found 9 differential metabolites when comparing VKH patients with healthy controls, and 26 differential metabolites were identified when comparing active VKH patients with inactive VKH patients. Pathway enrichment analysis showed that glycine, serine and threonine metabolism, and arginine and proline metabolism were significantly altered in VKH versus healthy controls. Lysine degradation and biotin metabolism pathways were significantly altered in active VKH versus inactive VKH. Furthermore, the receiver operating characteristic (ROC) curve analysis revealed that the combination of acetylglycine and gamma-glutamylalanine could differentiate VKH from healthy controls with an area under the curve (AUC) of 0.808. A combination of ureidopropionic acid and 5′-phosphoribosyl-5-amino-4-imidazolecarboxamide (AICAR) had an excellent AUC of 0.958 for distinguishing active VKH from inactive VKH. In summary, this study identified abnormal metabolites in urine of patients with VKH disease. Further studies are needed to confirm whether these metabolites are specific for this disease.
format Online
Article
Text
id pubmed-7947328
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79473282021-03-12 Identification of Urine Metabolic Biomarkers for Vogt-Koyanagi-Harada Disease Chang, Rui Zhu, Ying Xu, Jing Chen, Lin Su, Guannan Kijlstra, Aize Yang, Peizeng Front Cell Dev Biol Cell and Developmental Biology The diagnosis of Vogt-Koyanagi-Harada (VKH) disease is mainly based on a complex clinical manifestation while it lacks objective laboratory biomarkers. To explore the potential molecular biomarkers for diagnosis and disease activity in VKH, we performed an untargeted urine metabolomics analysis by ultra-high-performance liquid chromatography equipped with quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF/MS). Through univariate and multivariate statistical analysis, we found 9 differential metabolites when comparing VKH patients with healthy controls, and 26 differential metabolites were identified when comparing active VKH patients with inactive VKH patients. Pathway enrichment analysis showed that glycine, serine and threonine metabolism, and arginine and proline metabolism were significantly altered in VKH versus healthy controls. Lysine degradation and biotin metabolism pathways were significantly altered in active VKH versus inactive VKH. Furthermore, the receiver operating characteristic (ROC) curve analysis revealed that the combination of acetylglycine and gamma-glutamylalanine could differentiate VKH from healthy controls with an area under the curve (AUC) of 0.808. A combination of ureidopropionic acid and 5′-phosphoribosyl-5-amino-4-imidazolecarboxamide (AICAR) had an excellent AUC of 0.958 for distinguishing active VKH from inactive VKH. In summary, this study identified abnormal metabolites in urine of patients with VKH disease. Further studies are needed to confirm whether these metabolites are specific for this disease. Frontiers Media S.A. 2021-02-25 /pmc/articles/PMC7947328/ /pubmed/33718374 http://dx.doi.org/10.3389/fcell.2021.637489 Text en Copyright © 2021 Chang, Zhu, Xu, Chen, Su, Kijlstra and Yang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Chang, Rui
Zhu, Ying
Xu, Jing
Chen, Lin
Su, Guannan
Kijlstra, Aize
Yang, Peizeng
Identification of Urine Metabolic Biomarkers for Vogt-Koyanagi-Harada Disease
title Identification of Urine Metabolic Biomarkers for Vogt-Koyanagi-Harada Disease
title_full Identification of Urine Metabolic Biomarkers for Vogt-Koyanagi-Harada Disease
title_fullStr Identification of Urine Metabolic Biomarkers for Vogt-Koyanagi-Harada Disease
title_full_unstemmed Identification of Urine Metabolic Biomarkers for Vogt-Koyanagi-Harada Disease
title_short Identification of Urine Metabolic Biomarkers for Vogt-Koyanagi-Harada Disease
title_sort identification of urine metabolic biomarkers for vogt-koyanagi-harada disease
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947328/
https://www.ncbi.nlm.nih.gov/pubmed/33718374
http://dx.doi.org/10.3389/fcell.2021.637489
work_keys_str_mv AT changrui identificationofurinemetabolicbiomarkersforvogtkoyanagiharadadisease
AT zhuying identificationofurinemetabolicbiomarkersforvogtkoyanagiharadadisease
AT xujing identificationofurinemetabolicbiomarkersforvogtkoyanagiharadadisease
AT chenlin identificationofurinemetabolicbiomarkersforvogtkoyanagiharadadisease
AT suguannan identificationofurinemetabolicbiomarkersforvogtkoyanagiharadadisease
AT kijlstraaize identificationofurinemetabolicbiomarkersforvogtkoyanagiharadadisease
AT yangpeizeng identificationofurinemetabolicbiomarkersforvogtkoyanagiharadadisease